Cliff Asness's EBS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 989,677 shares of Emergent BioSolutions Inc. (EBS) worth $8.21 M, representing 0.00% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in EBS, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 586,246 shares. Largest reduction occurred in Q2 2024, reducing 591,387 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Emergent BioSolutions (EBS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Emergent BioSolutions (EBS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +511,648 | Add 107.03% | 989,677 | $8.30 |
| Q4 2025 | -108,217 | Reduce 18.46% | 478,029 | $12.36 |
| Q3 2025 | +586,246 | New Buy | 586,246 | $8.82 |
| Q3 2024 | -460,311 | Sold Out | 0 | $0.00 |
| Q2 2024 | -591,387 | Reduce 56.23% | 460,311 | $6.82 |
| Q1 2024 | +538,282 | Add 104.84% | 1.05 M | $2.47 |
| Q4 2023 | +334,298 | Add 186.64% | 513,416 | $2.40 |
| Q3 2023 | +76,007 | Add 73.71% | 179,118 | $3.38 |
| Q2 2023 | -99,308 | Reduce 49.06% | 103,111 | $7.35 |
| Q1 2023 | -346,708 | Reduce 63.14% | 202,419 | $10.07 |
| Q4 2022 | +298,253 | Add 118.89% | 549,127 | $11.71 |
| Q3 2022 | +136,235 | Add 118.84% | 250,874 | $20.99 |
| Q2 2022 | +28,688 | Add 33.38% | 114,639 | $30.31 |
| Q1 2022 | -409,549 | Reduce 82.65% | 85,951 | $41.06 |
| Q4 2021 | +132,387 | Add 36.46% | 495,500 | $43.47 |
| Q3 2021 | -311,166 | Reduce 46.15% | 363,113 | $50.07 |
| Q2 2021 | +307,445 | Add 83.81% | 674,279 | $62.99 |
| Q1 2021 | +184,746 | Add 101.46% | 366,834 | $92.26 |
| Q4 2020 | +129,074 | Add 243.47% | 182,088 | $89.60 |
| Q3 2020 | -20,817 | Reduce 28.20% | 53,014 | $103.33 |
| Q2 2020 | +1,006 | Add 1.38% | 73,831 | $79.09 |
| Q1 2020 | -23,128 | Reduce 24.10% | 72,825 | $57.86 |
| Q4 2019 | -33,113 | Reduce 25.66% | 95,953 | $53.95 |
| Q3 2019 | -57,026 | Reduce 30.64% | 129,066 | $52.28 |
| Q2 2019 | -73,800 | Reduce 28.40% | 186,092 | $48.31 |
| Q1 2019 | -19,284 | Reduce 6.91% | 259,892 | $50.52 |
| Q4 2018 | +9,430 | Add 3.50% | 279,176 | $59.28 |
| Q3 2018 | -7,190 | Reduce 2.60% | 269,746 | $65.83 |
| Q2 2018 | -62,466 | Reduce 18.40% | 276,936 | $50.49 |
| Q1 2018 | +4,918 | Add 1.47% | 339,402 | $52.65 |
| Q4 2017 | +68,050 | Add 25.54% | 334,484 | $46.47 |
| Q3 2017 | +146,945 | Add 122.98% | 266,434 | $40.45 |
| Q2 2017 | -31,367 | Reduce 20.79% | 119,489 | $33.91 |
| Q1 2017 | -40,945 | Reduce 21.35% | 150,856 | $29.04 |
| Q4 2016 | -13,444 | Reduce 6.55% | 191,801 | $32.84 |
| Q3 2016 | +90,494 | Add 78.86% | 205,245 | $31.53 |
| Q2 2016 | -16,388 | Reduce 12.50% | 114,751 | $28.12 |
| Q1 2016 | -110,015 | Reduce 45.62% | 131,139 | $36.35 |
| Q4 2015 | +3,213 | Add 1.35% | 241,154 | $40.01 |
| Q3 2015 | -53,427 | Reduce 18.34% | 237,941 | $28.49 |
| Q2 2015 | +5,603 | Add 1.96% | 291,368 | $32.95 |
| Q1 2015 | +17,302 | Add 6.44% | 285,765 | $28.76 |
| Q4 2014 | -8,173 | Reduce 2.95% | 268,463 | $27.23 |
| Q3 2014 | -101,100 | Reduce 26.76% | 276,636 | $21.31 |
| Q2 2014 | -77,600 | Reduce 17.04% | 377,736 | $22.46 |
| Q1 2014 | -21,000 | Reduce 4.41% | 455,336 | $25.27 |
| Q4 2013 | -5,300 | Reduce 1.10% | 476,336 | $22.99 |
| Q3 2013 | -40,365 | Reduce 7.73% | 481,636 | $19.05 |
| Q2 2013 | +522,001 | Add 0.00% | 522,001 | $14.42 |
| Q4 2012 | +261,801 | Add 0.00% | 261,801 | $16.04 |
Cliff Asness's Emergent BioSolutions Investment FAQs
Cliff Asness first purchased Emergent BioSolutions Inc. (EBS) in Q4 2012, acquiring 261,801 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Emergent BioSolutions Inc. (EBS) for 51 quarters since Q4 2012.
Cliff Asness's largest addition to Emergent BioSolutions Inc. (EBS) was in Q3 2025, adding 586,246 shares worth $5.17 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 989,677 shares of Emergent BioSolutions Inc. (EBS), valued at approximately $8.21 M.
As of the Q1 2026 filing, Emergent BioSolutions Inc. (EBS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Emergent BioSolutions Inc. (EBS) was 1,051,698 shares, as reported at the end of Q1 2024.